Access the full text.
Sign up today, get DeepDyve free for 14 days.
Tae Kim, W. Kim, J. Song, Yoon Rhee, G‐Y. Gong, Yoonje Cho, Sang Kim, Seong Kim, S. Hong, Y. Shong (2005)
The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinomaClinical Endocrinology, 63
Mingzhao Xing, W. Westra, R. Tufano, Y. Cohen, E. Rosenbaum, K. Rhoden, K. Carson, V. Vasko, A. Larin, G. Tallini, S. Tolaney, E. Holt, P. Hui, C. Umbricht, S. Basaria, Marge Ewertz, A. Tufaro, J. Califano, M. Ringel, M. Zeiger, D. Sidransky, P. Ladenson (2005)
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.The Journal of clinical endocrinology and metabolism, 90 12
A. Chakraborty, A. Narkar, R. Mukhopadhyaya, S. Kane, A. D'cruz, M. Rajan (2012)
BRAFV600E Mutation in Papillary Thyroid Carcinoma: Significant Association with Node Metastases and Extra Thyroidal InvasionEndocrine Pathology, 23
M. Rivera, J. Ricarte-Filho, R. Tuttle, I. Ganly, A. Shaha, J. Knauf, J. Fagin, R. Ghossein (2010)
Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension.Thyroid : official journal of the American Thyroid Association, 20 10
L. Fugazzola, D. Mannavola, V. Cirello, G. Vannucchi, M. Muzza, L. Vicentini, P. Beck‐Peccoz (2004)
BRAF mutations in an Italian cohort of thyroid cancersClinical Endocrinology, 61
Kuai-lu Lin, O. Wang, Xiao-hua Zhang, Xuan-xuan Dai, Xiao-qu Hu, J. Qu (2010)
The BRAF Mutation Is Predictive of Aggressive Clinicopathological Characteristics in Papillary Thyroid MicrocarcinomaAnnals of Surgical Oncology, 17
Amy Chen, A. Jemal, E. Ward (2009)
Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005Cancer, 115
SJ Kim, KE Lee, JP Myong (2012)
BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer., 36
R. Tufano, G. Teixeira, J. Bishop, K. Carson, Mingzhao Xing (2012)
BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-AnalysisMedicine, 91
W. Shen, Lauren Ogawa, D. Ruan, Insoo Suh, E. Kebebew, Q. Duh, O. Clark (2010)
Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations.Archives of surgery, 145 3
Yasuhiro Ito, H. Yoshida, Rie Maruo, S. Morita, T. Takano, M. Hirokawa, T. Yabuta, M. Fukushima, H. Inoue, C. Tomoda, M. Kihara, T. Uruno, T. Higashiyama, Y. Takamura, A. Miya, Kaoru Kobayashi, F. Matsuzuka, A. Miyauchi (2009)
BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.Endocrine journal, 56 1
Tae Kim, Y. Park, J. Lim, H. Ahn, Eun-Kyung Lee, You Lee, Kyung Kim, S. Hahn, Y. Youn, K. Kim, B. Cho, D. Park (2012)
The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancerCancer, 118
J. Sipos, E. Mazzaferri, E. Mazzaferri (2010)
Thyroid cancer epidemiology and prognostic variables.Clinical oncology (Royal College of Radiologists (Great Britain)), 22 6
S. Hundahl, I. Fleming, A. Fremgen, H. Menck (1998)
A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995Cancer, 83
L. Fugazzola, E. Puxeddu, N. Avenia, C. Romei, V. Cirello, A. Cavaliere, P. Faviana, D. Mannavola, S. Moretti, S. Rossi, M. Sculli, V. Bottici, P. Beck‐Peccoz, F. Pacini, A. Pinchera, F. Santeusanio, R. Elisei (2006)
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.Endocrine-related cancer, 13 2
M. Zeiger, E. Schneider (2012)
BRAF V600E Mutation Independently Predicts Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid CancerAnnals of Surgical Oncology, 20
L. Davies, Ms Welch, Drs Davies, Welch
Confidential. Do Not Distribute. Pre-embargo Material. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
L Davies, HG Welch (2006)
Increasing incidence of thyroid cancer in the United States, 1973-2002., 295
Tae Kim, W. Kim, J. Song, Yoon Rhee, G. Gong, Y. Cho, S. Kim, Seong Kim, S. Hong, Y. Shong (2005)
The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.Clinical endocrinology, 63 5
Zhong-Hua Lin, Yong-Ning Xin, Q. Dong, Qing Wang, Xiang-Jun Jiang, Shu-Hui Zhan, Ying Sun, S. Xuan (2010)
Association between HLA-DRB1 alleles polymorphism and hepatocellular carcinoma: a meta-analysisBMC Gastroenterology, 10
R. Elisei, C. Ugolini, D. Viola, C. Lupi, A. Biagini, R. Giannini, C. Romei, P. Miccoli, A. Pinchera, F. Basolo (2008)
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.The Journal of clinical endocrinology and metabolism, 93 10
L. Rowe, B. Bentz, J. Bentz (2007)
Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysisJournal of Clinical Pathology, 60
TH Kim, YJ Park, JA Lim (2012)
The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis., 118
L. Paulson, M. Shindo, K. Schuff, C. Corless (2012)
The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.Archives of otolaryngology--head & neck surgery, 138 1
E. Brzeziańska, D. Pastuszak-Lewandoska, K. Wojciechowska, M. Migdalska-Sęk, Anna Cyniak-Magierska, E. Nawrot, A. Lewiński (2007)
Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.Neuro endocrinology letters, 28 4
J. Ricarte-Filho, I. Ganly, M. Rivera, N. Katabi, Wei-jiang Fu, A. Shaha, R. Tuttle, J. Fagin, R. Ghossein (2011)
Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension.Thyroid : official journal of the American Thyroid Association, 22 6
C. Lupi, R. Giannini, C. Ugolini, A. Proietti, P. Berti, M. Minuto, G. Materazzi, R. Elisei, M. Santoro, P. Miccoli, F. Basolo (2007)
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.The Journal of clinical endocrinology and metabolism, 92 11
I. Nixon (2015)
Faculty Opinions recommendation of Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005.
L. Yip, M. Nikiforova, S. Carty, J. Yim, M. Stang, M. Tublin, Shane Lebeau, S. Hodak, J. Ogilvie, Y. Nikiforov (2009)
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.Surgery, 146 6
Michael Xing (2005)
BRAF mutation in thyroid cancer.Endocrine-related cancer, 12 2
ImportancePapillary thyroid carcinoma (PTC) is the most common endocrine neoplasm. B-type raf kinase (BRAF) V600E mutation has been proposed as a negative prognostic indicator in PTC, and patients harboring it should receive more aggressive initial therapy. ObjectiveTo assess the significance of BRAF V600E mutation in PTC in the largest US sample to date. DesignWe identified patients from our institution’s pathology archives diagnosed as having PTC and meeting criteria for BRAF mutation testing. Medical records were analyzed for BRAF status (positive or negative) and a list of standardized clinicopathologic features. ParticipantsA total of 429 patients with PTC at an academic medical center. Main Outcomes and MeasuresClinicopathologic features in patients with PTC with and without BRAF mutation. ResultsOf 429 cases with PTC, 314 (73.2%) were positive for the BRAF mutation and 115 (26.8%) tested negative. BRAF mutation was significantly associated with tumor margin positivity (P = .03) and lymph node metastasis (P = .002) on univariate analysis but not on multivariate study. BRAF mutation was a predictor of male sex (odds ratio [OR], 3.2; 95% CI, 1.4-7.2), total thyroidectomy (OR, 2.6; 95% CI, 1.1-6.2), and a negative predictor of follicular variant PTC (OR, 0.1; 95% CI, 0.1-0.4). There was no significant association between BRAF positivity and tumor multicentricity, lymphovascular invasion, extranodal extension, central neck involvement, advanced stage (stage III or IV), and distant metastasis. Conclusions and RelevanceBRAF V600E mutation has been extensively studied in relation to negative prognostic indicators in PTC, with no consistent relationship emerging. Two recent meta-analyses showed an overall association between BRAF status and aggressive disease features and called for tailoring treatment plans in patients accordingly. In this, the largest US study to date, BRAF status was not significantly associated with most clinicopathologic features suggestive of more aggressive disease.
JAMA Otolaryngology - Head & Neck Surgery – American Medical Association
Published: Nov 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.